Qyuns licenses antibody program in $780M deal
China's Qyuns Therapeutics has licensed an early-stage antibody program to Caldera Therapeutics in a deal worth up to $780 million. The agreement grants Caldera exclusive worldwide rights to develop and commercialize the drug candidates.
Xurve View
Insights:
Xurve View
QYUNS THERAPEUTICS CO LTD-H licensed an early-stage antibody program to United States biotech Caldera Therapeutics in a deal worth up to $780 million on Thursday morning. The agreement spans exclusive global rights for candidates targeting TL1A and IL-17 immune pathways. China-based Qyuns continues to expand its international out-licensing footprint following previous agreements.
